Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial
Suma Jacob, Jeremy Veenstra‐VanderWeele, Declan Murphy, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 3, pp. 199-210
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Chen-Chen Jiang, Lishan Lin, Sen Long, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 127
Oxytocin, Vasopressin, and Social Behavior: From Neural Circuits to Clinical Opportunities
Nicole Rigney, Geert J. De Vries, Aras Petrulis, et al.
Endocrinology (2022) Vol. 163, Iss. 9
Open Access | Times Cited: 95
Forensic and Pharmaceutical Risks in the Organization of Pharmacotherapy of Covid, Post-Covid and Long-Covid Disorders. COVID-19 and Vaccination Practice Standards.
Вікторія Шаповалова
SSP Modern Pharmacy and Medicine (2022) Vol. 2, Iss. 4, pp. 1-24
Open Access | Times Cited: 70
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder
Eric Hollander, Suma Jacob, Roger J. Jou, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 8, pp. 760-760
Open Access | Times Cited: 35
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)
Michelle Iffland, Nuala Livingstone, Mikaela Jorgensen, et al.
Cochrane library (2023) Vol. 2023, Iss. 10
Closed Access | Times Cited: 19
Oxytocin and vasopressin signaling in health and disease
Monika Perisic, Katrina Woolcock, Anke Hering, et al.
Trends in Biochemical Sciences (2024) Vol. 49, Iss. 4, pp. 361-377
Open Access | Times Cited: 7
Cannabinoid treatment for the symptoms of autism spectrum disorder
Adi Aran, Dalit Cayam Rand
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 1, pp. 65-79
Closed Access | Times Cited: 6
Towards the convergent therapeutic potential of G protein‐coupled receptors in autism spectrum disorders
Anil Annamneedi, Caroline Gora, Ana Dudas, et al.
British Journal of Pharmacology (2023)
Open Access | Times Cited: 15
Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder
Russell H. Tobe, Yajing Zhu, Teresa Gleissl, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 8, pp. 1201-1216
Open Access | Times Cited: 11
Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options
Liliana Dell’Osso, Chiara Bonelli, Federico Giovannoni, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 324-324
Open Access
A narrative review of the placebo effect: historical roots, current applications, and emerging insights
Cagri Ozpolat, Yagmur Okcay, Kemal Gökhan Ulusoy, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program
Suma Jacob, Evdokia Anagnostou, Eric Hollander, et al.
Molecular Autism (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study
Christopher J. Keary, Lynne M. Bird, Marie‐Claire Y. de Wit, et al.
European Journal of Paediatric Neurology (2023) Vol. 47, pp. 6-12
Closed Access | Times Cited: 7
Vasopressin receptor antagonists: a patent summary (2018-2022)
Ferenc Baska, Éva Bozó, Tamás Patócs
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 5, pp. 385-395
Closed Access | Times Cited: 6
Vasopressin as Possible Treatment Option in Autism Spectrum Disorder
Kristóf László, Dávid Vörös, Pedro Correia, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2603-2603
Open Access | Times Cited: 6
Rol de la terapia farmacológica en los trastornos del espectro autista
Elisa Reyes, Lorena Pizarro
Revista Médica Clínica Las Condes (2022) Vol. 33, Iss. 4, pp. 387-399
Open Access | Times Cited: 4
Placebo effects and participant heterogeneity in clinical trials of autism spectrum disorder
Eva Loth
The Lancet Psychiatry (2022) Vol. 9, Iss. 3, pp. 184-185
Closed Access | Times Cited: 3
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations
Franziska Schaedeli Stark, Clarisse Chavanne, Michael Derks, et al.
Journal of Pharmacokinetics and Pharmacodynamics (2024) Vol. 51, Iss. 3, pp. 227-242
Open Access
Mechanism‐based interventions for ASD cannot be implemented using conventional trial designs
Jan J. Sprengers, Lisa Geertjens, Hilgo Bruining
Autism Research (2024) Vol. 17, Iss. 2, pp. 202-203
Closed Access
Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity
Junqi Hu, Yinlong Li, Chenchen Dong, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 4014-4027
Open Access
EEG Biomarkers for Autism: Rational, Support, and the Qualification Process
Caitlin M. Hudac, Sara Jane Webb
Advances in neurobiology (2024), pp. 545-576
Closed Access
Autism spectrum disorder
Scott M. Myers, Thomas D. Challman
Elsevier eBooks (2024), pp. 589-683
Closed Access
Neuropeptides in mental health: CRF, AVP, and OXT
Elizabeth A. D. Hammock
Elsevier eBooks (2022), pp. 616-621
Closed Access | Times Cited: 1
The Vasopressin V1A Receptor and Aggression
Oliver Tan, Michael T. Bowen
Springer eBooks (2023), pp. 1-26
Closed Access
The Vasopressin V1A Receptor and Aggression
Oliver Tan, Michael T. Bowen
Springer eBooks (2023), pp. 1647-1672
Closed Access
Page 1 - Next Page

Scroll to top